Copper and myeloperoxidase-modified LDLs activate Nrf2 through different pathways of ros production in macrophages

Antioxidants and Redox Signaling

Volumn 13, Issue 10, 2010, Pages 1491-1502

  Calay, Damien ^a   Rousseau, Alexandre ^b   Mattart, Laurine ^a   Nuyens, Vincent ^b   Delporte, Cédric ^c   Van Antwerpen, Pierre ^c   Moguilevsky, Nicole ^a   Arnould, Thierry ^a   Boudjeltia, Karim Zouaoui ^b   Raes, Martine ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b CHU Andre Vesale   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; HEME OXYGENASE 1; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR NRF2; TROLOX C;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; FOAM CELL; GCLM GENE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; CELLS, CULTURED; COPPER; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MACROPHAGES; MICE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PEROXIDASE; REACTIVE OXYGEN SPECIES;

MURINAE;

EID: 77957737755     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2971     Document Type: Article

References (49)

1. Akiba S, Yoneda Y, Ohno S, Nemoto M, and Sato T. Oxidized LDL activates phospholipase A2 to supply fatty acids required for cholesterol esterification. J Lipid Res 44: 1676-1685, 2003.
2. Alam J and Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36: 166-174, 2007.
3. Berliner JA and Heinecke JW. The role of oxidized lipopro-teins in atherogenesis. Free Radic Biol Med 20: 707-727, 1996.
4. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, and Lusis AJ. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107: 419-430, 2001.
5. Carr AC, Myzak MC, Stocker R, McCall MR, and Frei B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett 487: 176-180, 2000.
6. Chan K and Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 96: 12731-12736, 1999.
7. Chung HT, Pae HO, and Cha YN. Role of heme oxygenase-1 in vascular disease. Curr Pharm Des 14: 422-428, 2008.
8. Daugherty A, Dunn JL, Rateri DL, and Heinecke JW. Mye-loperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444, 1994.
9. Deng TL, Yu L, Ge YK, Zhang L, and Zheng XX. Intracellular-free calcium dynamics and F-actin alteration in the formation of macrophage foam cells. Biochem Biophys Res Commun 338: 748-756, 2005.
10. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
11. Franco R, Schoneveld OJ, Pappa A, and Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 113: 234-258, 2007.
12. Hazen SL and Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99: 2075-2081, 1997.
13. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, and Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: Implication for native LDL oxidation. Circ Res 93: 1225-1232, 2003.
14. Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, and Mann GE. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 94: 609-616, 2004.
15. Jefferies H, Coster J, Khalil A, Bot J, McCauley RD, and Hall JC. Glutathione. ANZ J Surg 73: 517-522, 2003.
16. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
17. Kim C, Kim JY, and Kim JH. Cytosolic phospholipase A(2), lipoxygenase metabolites, and reactive oxygen species. BMB Rep 41: 555-559, 2008.
18. Klinkner AM, Waites CR, Kerns WD, and Bugelski PJ. Evidence of foam cell and cholesterol crystal formation in mac-rophages incubated with oxidized LDL by fluorescence and electron microscopy. J Histochem Cytochem 43: 1071-1078, 1995.
19. Lee JM and Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37: 139-143, 2004.
20. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, and Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272: 3520-3526, 1997.
21. Lupo G, Nicotra A, Giurdanella G, Anfuso CD, Romeo L, Biondi G, Tirolo C, Marchetti B, Ragusa N, and Alberghina M. Activation of phospholipase A(2) and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells. Biochim Biophys Acta 1735: 135-150, 2005.
22. Lusis AJ. Atherosclerosis. Nature 407: 233-241, 2000.
23. Maines MD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554, 1997.
24. Malle E, Marsche G, Arnhold J, and Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived ox-idants and reagent hypochlorous acid. Biochim Biophys Acta 1761: 392-415, 2006.
25. Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, and Malle E. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipo-protein. J Biol Chem 278: 47562-47570, 2003.
26. Maziere C and Maziere JC. Activation of transcription factors and gene expression by oxidized low-density lipopro-tein. Free Radic Biol Med 2008.
27. McMillen TS, Heinecke JW, and LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 111: 2798-2804, 2005.
28. Moguilevsky N, Zouaoui Boudjeltia K, Babar S, Delree P, Legssyer I, Carpentier Y, Vanhaeverbeek M, and Ducobu J. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Commun 323: 1223-1228, 2004.
29. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 25: 1786-1795, 2005.
30. Morse D and Choi AM. Heme oxygenase-1: The "emerging molecule" has arrived. Am J Respir Cell Mol Biol 27: 8-16, 2002.
31. Muller K, Dulku S, Hardwick SJ, Skepper JN, and Mitch-inson MJ. Changes in vimentin in human macrophages during apoptosis induced by oxidised low density lipopro-tein. Atherosclerosis 156: 133-144, 2001.
32. Nicholls SJ and Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25: 1102-1111, 2005.
33. Sharif O, Bolshakov VN, Raines S, Newham P, and Perkins ND. Transcriptional profiling of the LPS induced NF-kappaB response in macrophages. BMC Immunol 8: 1, 2007.
34. Shiose A and Sumimoto H. Arachidonic acid and phos-phorylation synergistically induce a conformational change of p47phox to activate the phagocyte NADPH oxidase. J Biol Chem 275: 13793-13801, 2000.
35. Singh U and Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 13: 129-142, 2006.
36. Stocker R and Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004.
37. Thomas CE. The influence of medium components on Cu(2\+)-dependent oxidation of low-density lipoproteins and its sensitivity to superoxide dismutase. Biochim Biophys Acta 1128: 50-57, 1992.
38. Townsend DM, Tew KD, and Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 57: 145-155, 2003.
39. Vaes M, Zouaoui Boudjeltia K, Van Antwerpen P, Babar S, Deger F, Vanhaeverbeek M, and Ducobu J. Low-density lipoprotein oxidation by myeloperoxidase occurs in the blood circulation during hemodialysis. Atherosclerosis Supplements 7: 525, 2006.
40. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
41. Wittwer J and Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 77: 67-77, 2007.
42. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15: 212-216, 1976.
43. Yamaguchi M, Sato H, and Bannai S. Induction of stress proteins in mouse peritoneal macrophages by oxidized low-density lipoprotein. Biochem Biophys Res Commun 193: 1198-1201, 1993. (Pubitemid 23209721)
44. Yan LJ, Lodge JK, Traber MG, Matsugo S, and Packer L. Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. J Lipid Res 38: 992-1001, 1997.
45. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, and Brown MS. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75: 187-197, 1993.
46. Zarev S, Bonnefont-Rousselot D, Jedidi I, Cosson C, Couturier M, Legrand A, Beaudeux JL, and Therond P. Extent of copper LDL oxidation depends on oxidation time and copper=LDL ratio: chemical characterization. Arch Biochem Biophys 420: 68-78, 2003.
47. Ziouzenkova O, Sevanian A, Abuja PM, Ramos P, and Es-terbauer H. Copper can promote oxidation of LDL by markedly different mechanisms. Free Radic Biol Med 24: 607-623, 1998.
48. Zouaoui Boudjeltia K, Legssyer I, Van Antwerpen P, Kisoka RL, Babar S, Moguilevsky N, Delree P, Ducobu J, Remacle C, Vanhaeverbeek M, and Brohee D. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol 84: 805-812, 2006.
49. Zouaoui Boudjeltia K, Tragas G, Babar S, Moscariello A, Nuyens V, Van Antwerpen P, Gilbert O, Ducobu J, Brohee D, Vanhaeverbeek M, and Van Meerhaeghe A. Effects of oxygen therapy on systemic inflammation and myeloperoxidase modified LDL in hypoxemic COPD patients. Atherosclerosis 2009.